Petrina Chu

Petrina Chu

Auto-generated profile, based on publicly available information

Petrina Chu

Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology C Neuroscience, King’s College London, London, UK

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2022 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
PCPetrina Chu
Petrina Chu
SCSharon Louise Cadogan
Sharon Louise Cadogan
CWCharlotte Warren-Gash
Charlotte Warren-Gash
Background: Associations between human herpesviruses (HHVs) and cardiovascular disease/mortality have been reported, but evidence is inconsistent. We investigated associations between 3 common herpesviruses and (1) incident stroke or myocardial infarction (MI) and (2) all-cause mortality. Methods: We included participants from the UK Biobank Infectious Disease pilot study with valid serum antibody (IgG) measurements taken at cohort entry (2006–2010) for herpes simplex virus type 1 (HSV1), varicella zoster virus (VZV), and cytomegalovirus (CMV). Linked hospital and mortality records up to December 30 2019 provided information on rates of (1) incident first stroke or MI and (2) all-cause mortality. Hazard ratios (HRs) from Cox proportional hazards regression models were used to assess relationships between (1) HHV seropositivity, (2) HHV titer and incident stroke/MI, and death outcomes. Fully adjusted models accounted for sociodemographic information (age, sex, ethnicity, education, deprivation quintile, birthplace, population density), baseline comorbidities (including diabetes and hypertension), smoking status, body mass index, and serum cholesterol. Results: Of 9429 study participants (56% female, 95% White, median age 58 years), 41% were seropositive for all 3 HHVs. Human herpesvirus seropositivity was not associated with stroke/MI (fully adjusted HRs and 95% confidence intervals [CIs]: HSV1 = 0.93 [CI, 0.72–1.22], VZV = 0.78 [CI, 0.51–1.20], CMV = 0.91 [CI, 0.71–1.16]) or all-cause mortality (HSV1 = 1.21 [CI, 1.00–1.47], VZV = 0.79 [CI, 0.58–1.07], CMV = 0.90 [CI, 0.76–1.06]). Human herpesvirus titers were not associated with outcomes. Conclusions: In this mostly White UK Biobank subset, neither HHV seropositivity nor titers were associated with stroke/MI or all-cause mortality.

6 August 2026 in Nature Medicine
Verified
Journal Article
Open access
JRJames J. Rucker
James J. Rucker
TMTim Mantingh
Tim Mantingh
JKJess Kerr-Gaffney
Jess Kerr-Gaffney
CBCatherine Bird
Catherine Bird
PCPetrina Chu
Petrina Chu
AYAllan H. Young
Allan H. Young
Psilocybin-assisted therapy may be a promising new treatment for treatment-resistant depression. We examined the feasibility of administering a single 25-mg dose of psilocybin or placebo with psychological support in a randomized controlled trial design with 6 weeks of follow-up. A two-arm, double-blind, randomized, placebo-controlled feasibility trial was conducted at one National Health Service (NHS) site in England. Eligible participants met Diagnostic and Statistical Manual of Mental Disorders , Fifth Edition (DSM-5) criteria for major depressive disorder and had an inadequate response to ≥2 antidepressant treatments or ≥1 antidepressant plus ≥1 psychotherapy. Participants received 25-mg psilocybin or placebo with preparation, dosing support and integration. Primary outcomes were recruitment, retention and estimation of the Montgomery−Åsberg Depression Rating Scale (MADRS) variance. A multilevel regression analysis with an intention-to-treat population was used. Sixty participants were randomized (1:1), balanced by age, sex and prior psilocybin exposure, and 59 of 60 participants completed the MADRS at all follow-up visits. The adjusted between-group difference at week 3 on the MADRS was −10.41 (95% confidence interval: −14.86 to −5.95; Cohen’s d = −1.70), favoring psilocybin, which was sustained at week 6. In total, 123 and 164 nonserious adverse events occurred in the placebo and psilocybin arms, respectively. Findings support a future confirmatory trial. EudraCT no.: 2018-003573-97 .

11 September 2023 in JMIR Pediatrics and Parenting
Verified
Journal Article
Open access
KKKatarzyna Kostyrka-Allchorne
Katarzyna Kostyrka-Allchorne
PCPetrina Chu
Petrina Chu
CBClaire Ballard
Claire Ballard
NLNancy Lean
Nancy Lean
BFBlandine French
Blandine French
ESEdmund Sonuga-Barke
Edmund Sonuga-Barke
Background: The Structured E-Parenting Support (STEPS) app provides support for parents of children with elevated hyperactivity, impulsivity, inattention, and conduct problems who are awaiting clinical assessment. STEPS will be evaluated in a randomized controlled trial (RCT) within the Online Parent Training for the Initial Management of ADHD Referrals (OPTIMA) research program in the United Kingdom. Phase 1 of the OPTIMA tested the feasibility of participants’ recruitment and the app’s usability. Objective: This study aimed to adapt a digital routine clinical monitoring system, myHealthE, for research purposes to facilitate waitlist recruitment; test using remote methods to screen and identify participants quickly and systematically; pilot the acceptability of the recruitment and assessment protocol; and explore the usability of STEPS. Methods: myHealthE was adapted to screen patients’ data. Parents’ and clinicians’ feedback on myHealthE was collected, and information governance reviews were conducted in clinical services planning to host the RCT. Potential participants for the observational feasibility study were identified from new referrals using myHealthE and non-myHealthE methods. Descriptive statistics were used to summarize the demographic and outcome variables. We estimated whether the recruitment rate would meet the planned RCT sample size requirement (n=352). In addition to the feasibility study participants, another group of parents was recruited to assess the STEPS usability. They completed the adapted System Usability Scale and responded to open-ended questions about the app, which were coded using the Enlight quality construct template. Results: Overall, 124 potential participants were identified as eligible: 121 (97.6%) via myHealthE and 3 (2.4%) via non-myHealthE methods. In total, 107 parents were contacted, and 48 (44.9%) consented and were asked if, hypothetically, they would be willing to participate in the OPTIMA RCT. Of the 28 feasibility study participants who provided demographic data, 21 (75%) identified as White. Their children had an average age of 8.4 (SD 1.7) years and 65% (31/48) were male. During the primary recruitment period (June to July 2021) when 45 participants had consented, 38 (84%) participants agreed hypothetically to take part in the RCT (rate of 19/mo, 95% CI 13.5-26.1), meeting the stop-go criterion of 18 participants per month to proceed with the RCT. All parents were satisfied or very satisfied with the study procedures. Parents (n=12) recruited to assess STEPS’ usability described it as easy to navigate and use and as having an attractive combination of colors and visual design. They described the content as useful, pitched at the right level, and sensitively presented. Suggested improvements included adding captions to videos or making the recorded reflections editable. Conclusions: Remote recruitment and study procedures for testing a parenting intervention app are feasible and acceptable for parents. The parents felt that STEPS was a useful and easy-to-use digital parenting support tool. International Registered Report Identifier (IRRID): RR2-10.1186/s40814-021-00959-0

20 December 2024 in medRxiv
Verified
Preprint
Open access
PDF file
CAChristopher P Albertyn
Christopher P Albertyn
TGTa-Wei Guu
Ta-Wei Guu
PCPetrina Chu
Petrina Chu
BCByron Creese
Byron Creese
Allan YoungAllan Young
Allan Young
DADag Aarsland
Dag Aarsland
Background Alzheimer’s Disease (AD) patients often experience clinically significant agitation, leading to distress, increased healthcare costs, and earlier institutionalisation. Current treatments have limited efficacy and significant side effects. Cannabinoid-based therapies, such as the nabiximols oral spray (brand name: Sativex®; 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)), offer potential alternatives. Methods The ‘Sativex® for Agitation & Aggression in Alzheimer’s Dementia’ (STAND) trial was a randomised, double-blind, placebo-controlled, feasibility study conducted in UK care homes. Participants with probable AD and significant agitation were randomised to receive placebo or nabiximols for 4 weeks on an up-titrated schedule, followed by a 4-week observation period. This trial is registered with ISRCTN 7163562. Findings Between October 2021 and June 2022, 53 candidates were assessed; 29 met eligibility criteria and were randomised. No participants withdrew, and adherence was high, and was generally feasible to deliver. The intervention was well tolerated, with no safety concerns reported. Interpretation Despite significant COVID-19 pandemic related challenges, administering nabiximols to advanced AD patients with agitation demonstrated feasibility and safety. Although no statistically significant treatment effects were observed, indications of positive clinical effects were noted. These findings support further investigation into cannabinoid-based therapies for agitation in AD.

11 November 2025 in British Journal of General Practice
Verified
Journal Article
Open access
PDF file
KBKarol Basta
Karol Basta
HDHiten Dodhia
Hiten Dodhia
JCJames Crompton
James Crompton
DWDavid Whitney
David Whitney
PCPetrina Chu
Petrina Chu
EIEse Iyasere
Ese Iyasere
Background: Vaccination is a cornerstone of childhood public health. However, uptake has declined across the UK, with urban, deprived, and ethnically diverse communities facing unique barriers, exacerbated by the COVID-19 pandemic. Aim: To identify socioeconomic and clinical predictors of incomplete and untimely childhood vaccination between 2010 and 2023. Design and setting: This was a cross-sectional study using electronic health records from 40 general practices in Lambeth, an ethnically diverse London borough. Method: Routinely collected data for 37 912 children eligible for vaccines by age 5 years were analysed. Multivariable logistic regression assessed associations between predictors and (a) vaccination uptake and (b) timeliness, defined as receipt within 3 months of the scheduled age. Results: Of eligible children, 61.0% ( N = 23 119/37 912) were fully vaccinated; of these, 60.8% ( N = 14 062/23 119) were vaccinated on time. Lower uptake was associated with deprivation (most versus least deprived: adjusted odds ratio [AOR] 0.66, 95% confidence interval (CI) = 0.51 to 0.84), born outside the UK versus UK born (AOR 0.10, 95% CI = 0.08 to 0.12), and ethnicities other than White British (for example, Black Caribbean: AOR 0.30, 95% CI = 0.25 to 0.36). Children with clinical comorbidities had higher uptake (for example primary care-managed comorbidity: AOR 1.58, 95% CI = 1.46 to 1.71). Timeliness patterns differed: among those vaccinated, children born outside the UK and those from African, Caribbean, and Mixed ethnic backgrounds had higher odds of timely vaccination. Conclusion: Different predictors for uptake and timeliness highlight the need for strategies addressing both access and timely delivery. Local data should inform targeted, place-based interventions. Culturally competent services, integrated into routine primary care and codesigned with communities, are recommended.

14 March 2023 in JMIR Preprints
Verified
Preprint
Open access
KKKatarzyna Kostyrka-Allchorne
Katarzyna Kostyrka-Allchorne
PCPetrina Chu
Petrina Chu
CBClaire Ballard
Claire Ballard
NLNancy Lean
Nancy Lean
BFBlandine French
Blandine French
ESEdmund Sonuga-Barke
Edmund Sonuga-Barke
BACKGROUND The Structured E-Parenting Support (STEPS) app provides support for parents of children with elevated hyperactivity, impulsivity, inattention, and conduct problems who are awaiting clinical assessment. STEPS will be evaluated in a randomized controlled trial (RCT) within the Online Parent Training for the Initial Management of ADHD Referrals (OPTIMA) research program in the United Kingdom. Phase 1 of the OPTIMA tested the feasibility of participants’ recruitment and the app’s usability. OBJECTIVE This study aimed to adapt a digital routine clinical monitoring system, myHealthE, for research purposes to facilitate waitlist recruitment; test using remote methods to screen and identify participants quickly and systematically; pilot the acceptability of the recruitment and assessment protocol; and explore the usability of STEPS. METHODS myHealthE was adapted to screen patients’ data. Parents’ and clinicians’ feedback on myHealthE was collected, and information governance reviews were conducted in clinical services planning to host the RCT. Potential participants for the observational feasibility study were identified from new referrals using myHealthE and non-myHealthE methods. Descriptive statistics were used to summarize the demographic and outcome variables. We estimated whether the recruitment rate would meet the planned RCT sample size requirement (n=352). In addition to the feasibility study participants, another group of parents was recruited to assess the STEPS usability. They completed the adapted System Usability Scale and responded to open-ended questions about the app, which were coded using the Enlight quality construct template. RESULTS Overall, 124 potential participants were identified as eligible: 121 (97.6%) via myHealthE and 3 (2.4%) via non-myHealthE methods. In total, 107 parents were contacted, and 48 (44.9%) consented and were asked if, hypothetically, they would be willing to participate in the OPTIMA RCT. Of the 28 feasibility study participants who provided demographic data, 21 (75%) identified as White. Their children had an average age of 8.4 (SD 1.7) years and 65% (31/48) were male. During the primary recruitment period (June to July 2021) when 45 participants had consented, 38 (84%) participants agreed hypothetically to take part in the RCT (rate of 19/mo, 95% CI 13.5-26.1), meeting the stop-go criterion of 18 participants per month to proceed with the RCT. All parents were satisfied or very satisfied with the study procedures. Parents (n=12) recruited to assess STEPS’ usability described it as easy to navigate and use and as having an attractive combination of colors and visual design. They described the content as useful, pitched at the right level, and sensitively presented. Suggested improvements included adding captions to videos or making the recorded reflections editable. CONCLUSIONS Remote recruitment and study procedures for testing a parenting intervention app are feasible and acceptable for parents. The parents felt that STEPS was a useful and easy-to-use digital parenting support tool. INTERNATIONAL REGISTERED REPORT RR2-10.1186/s40814-021-00959-0